Jubilant Radiopharma’s Post

𝐖𝐞 𝐚𝐫𝐞 𝐩𝐥𝐞𝐚𝐬𝐞𝐝 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐲𝐨𝐮 𝐰𝐢𝐭𝐡 𝐚𝐧 𝐮𝐩𝐝𝐚𝐭𝐞 𝐨𝐧 𝐨𝐮𝐫 𝐜𝐨𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐁. 𝐁𝐫𝐚𝐮𝐧 𝐌𝐞𝐥𝐬𝐮𝐧𝐠𝐞𝐧 𝐀𝐆.   The integration of our VariPol unit marks a significant step forward, replacing an older Krüss device, and highlights the trust B. Braun places in our technology for their sophisticated analytical needs. The enthusiasm from the B. Braun team was palpable during the training session led by our specialist Niels R. Carstensen, attended by five dedicated employees. Their eagerness to start working with the VariPol—and soon, the VariRef—underscores the potential impact our devices have in supporting their mission-critical healthcare applications.   Alongside the two VariPol units already enhancing glucose solution analysis, we're preparing to install the VariRef device. This addition is also set to be operational in their Melsungen facility, where it will play a critical role in analyzing infusion solutions containing saline and glucose.   B. Braun Melsungen AG's decision to integrate our technologies into their processes is a testament to their effectiveness in ensuring high-quality standards in healthcare.   #SchmidtHaensch #VariPol #VariRef #HealthcareInnovation #GlucoseAnalysis

AdAlta Ltd CEO and Managing Director Dr Tim Oldham spoke to Proactive about the results of AD-214 dose simulation studies that support the potential efficacy of the planned intravenous dose regimen for treating fibrotic disease.   Dr Oldham notes that this is the most significant data AdAlta has received this year, helping to determine a dose and dosing regimen ahead of Phase II, that is likely to be both efficacious and suitable for clinician and patient adoption. He explains that the model of AD-214 distribution and receptor blocking is a big move forward in de-risking Phase II studies for partners.   The model also allows the exploration of enhanced routes of administration, and suggests the potential for more convenient subcutaneous administration. This could be available in time for Phase III if a partner wishes to progress this option.   This data is exciting news for AdAlta and adds real momentum to its partnering program for both strategic pharma opportunities and project financing options going forward. Click below to watch. #AdAlta #ASX #1AD #fibrosis

CE Opportunity: Hosted by Aerogen How to Deliver Aerosolized Medications through High Flow Nasal Cannula. Speaker: Arzu Ari, Ph.D., RRT, PT, CPFT, FAARC, FCCP Registration Link: http://l.ead.me/RCed1019 1.00 CRCE/CSRT Credit In this Aerogen Sponsored Webinar with Dr. Ari, she will discuss the following learner objectives: 1. Describe factors affecting aerosol delivery via High Flow Nasal Cannula (HFNC). 2. Provide strategies for aerosol drug delivery during HFNC based on the best evidence. #RCWEEK2023

After Resmetirom, hopefully we will have a few other approveed options for MASH Rx soon. Major Phase 2 MASH Trial Updates: Tirzepatide: 🔸44-62% resolution of MASH at 52 wks. 🔸~50% of participants ≥ 1 stage improvement in fibrosis at 52 wks. Survodutide: 🔸~35% of participants with ≥ 1 stage improvement in fibrosis at 48 wks.

Reminder - SIO Webinar: How to Maximize the Use of EfficaSafe (a new SIO membership benefit). June 24, 2024 - 3-4 pm ET Register here: https://zurl.co/lbUa #integrativeoncology #druginteractions #herbs #dietarysupplements #integrativemedicine

#OPGN - 500 Gain In Premarket Session Heres Why Precision Medicine OpGen Stock Is Soaring Benzinga OpGen Inc (NASDAQ: OPGN) stock is trading higher following two SEC filings from the precision medicine company. The company has rece... October 12, 2023 at 12:36PM #StockMarket #MWN

“I am data oriented and we don’t know how Vabysmo is compared to HD eylea as we cannot cross trial compare! We will need a head to head trial to see which molecule is better! “ Arshad Khanani Does the ASRS 2023 AND vs OR paper give you evidence that Eylea HD is inferior than Vabysmo in nAMD in durability? Candela failed to get Vabysmo durability in nAMD Is the CST in Photon sawtooth 🦷 compared to Yosemite and Rhine? Stable CST is better than “YoYo” DME. BCVA is a low bar to use. The FDA gave Eylea HD an DR indication and not Vabysmo How does that make sense to harm Vabysmo and help Eylea HD without proof? A study of DR for Vabysmo alone would be difficult to recruit in 2023 if not impossible. Vabymso DR with DME did meet the endpoint.

Purastat: A 'Game-Changer' for Endoscopists? In the critical domain of gastroenterology, ERCP (Endoscopic Retrograde Cholangiopancreatography) is a cornerstone procedure for the diagnosis and treatment of conditions affecting the biliary and pancreatic ductal systems. However, the challenge of managing bleeding during these procedures can significantly impact patient outcomes and procedural efficiency. Enter Purastat, a revolutionary hemostatic agent that is transforming the ERCP landscape. This innovative product offers numerous benefits, enhancing both patient safety and procedural success. Here's why Purastat is becoming an indispensable tool in ERCP: 🔹 Rapid Hemostasis: Purastat's unique peptide formulation provides immediate action, facilitating quick bleeding control, which is crucial during complex ERCP procedures. 🔹 Enhanced Visibility: With its clear application, Purastat improves the endoscopic field of view, allowing for precise interventions and reducing the risk of complications. 🔹 Ease of Use: PuraStat comes in a ready to use syringe with no preparation time. Its simple and effective application process integrates seamlessly into ERCP procedures, ensuring that the focus remains on patient care without additional procedural complexity. 🔹 Patient Safety: By minimizing bleeding and improving procedural outcomes, Purastat contributes to enhanced patient safety and quicker recovery times. The integration of Purastat into ERCP procedures marks a significant advancement in gastrointestinal healthcare, merging efficiency, safety, and innovation. Experience the impact of Purastat through the eyes of healthcare professionals. Dr. Sharaiha shares her insights and experiences, along with many others, in a series of testimonials available on our YouTube channel attached below. #Gastroenterology #ERCP #Purastat #HealthcareInnovation #PatientSafety

Developing a new drug takes long-term commitment but the reward can be life-changing. Watch this video as Race Oncology CEO speaks with HotCopper to break down the drug development process and biotech companies' appeal to the investors. #oncologydrugs #biotech #investment

Check Out our NEW Stago Scientific Short! Dr. Michael Gulseth discusses key insights on anticoagulation, including choosing between DOACs and VKAs, dispelling DOAC misconceptions, and highlighting the role of anti-Xa testing. Watch Now! https://lnkd.in/dH7NydEQ. #Anticoagulation #MedicalInsights #Stago #PharmacyWeek